Z.ai nears $1bn sales defying Western AI business model
Chinese AI startup Z.ai is approaching $1bn in annual sales by open-sourcing its best models, a commercialisation path that challenges the loss-heavy, closed-source approach dominating Western tech.
Z.ai is on track to become the first independent Chinese AI firm to reach roughly $1bn in annual sales. The figure is a forward projection based partly on annualised recurring revenue rather than booked sales, but the underlying growth is sharp. Revenue hit about 724m yuan, or roughly $100m, in 2025, up 132% on the year.
The company is achieving this while giving its most capable models, including GLM-5.2, away as open-source software. In the Western AI sector, releasing frontier models for free is widely viewed as incompatible with building a defensible business. Z.ai is betting the opposite: that free models drive adoption, which in turn sells cloud infrastructure, technical support and on-premises installations.
The strategy is translating into enterprise contracts. A large share of Z.ai's revenue comes from on-premises deployments for state-owned enterprises and financial institutions. Meanwhile, annualised recurring revenue from its open platform reached 1.7bn yuan, growing sixtyfold in a single year.
For European investors and tech executives, Z.ai’s trajectory undermines the prevailing US-led assumption that AI commercialisation requires closed ecosystems and massive cash burn. It suggests China’s advantage in the global AI race is speed to market and enterprise monetisation, rather than merely state subsidies.
Significant risks remain. The company is still loss-making, with JPMorgan not projecting a profit until 2028, when it forecasts revenue of 30.9bn yuan. Much of its customer base relies on state-owned buyers, blurring the line between genuine commercial demand and government backing.
Z.ai's valuation has surged past $112bn after a rally of over 1,000% since its January listing, a figure that prices in flawless execution of aggressive targets. The company also faces a brutal domestic price war, with cheap Chinese models aggressively undercutting each other and US labs. Reaching $1bn in sales is a milestone, but converting that scale into profit in a deflationary market remains the harder test.
